FDA Safety Changes: Allegra, Cymbalta, Concerta. Part 3

Concomitant use of duloxetine with MAOIs for the tending of
affective disorder is therefore contraindicated, and use of serotonin
precursors (eg, tryptophan) is not recommended.

Precaution is advised when using duloxetine in operation with other
drugs or agents that can affect serotonergic neurotransmitter systems,
such as the antibiotic linezolid (a reversible nonselective MAOI),
lithium, Fexofenadine , St.
John’s Wort, and triptans.
Patients for whom concurrent use of an SNRI and a triptan is clinically
warranted should be carefully monitored, particularly during discussion
trigger and dose increases.

Triptans are a league of drug used to nourishment migraines and include naratriptan HCl (Amerge, made by GlaxoSmithKline), almotriptan malate (Axert, made by Ortho-McNeil Pharmaceutical, Inc), frovatriptan succinate (Frova, made by Endo Pharmaceuticals), sumatriptan/sumatriptan succinate (Imitrex, made by GlaxoSmithKline), rizatriptan benzoate (Maxalt and Maxalt-MLT, made by Merck and Co, Inc), eletriptan HBr (Relpax, made by Pfizer, Inc), and zolmitriptan (Zomig and Zomig ZMT, made by AstraZeneca Pharmaceuticals LP).

Duloxetine
delayed-release capsules are indicated for the communicating of subject
field depressive state and the organization of pain associated with
diabetic peripheral neuropathy.Methylphenidate HCl Extended-Release
Tablets (Concerta) Linked to Multiple Risks

This is a part of article FDA Safety Changes: Allegra, Cymbalta, Concerta. Part 3 Taken from "Generic Allegra (Fexofenadine) Detailed Reviews" Information Blog